In This Article:
Charles River Laboratories (CRL) reported $984.17 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 2.7%. EPS of $2.34 for the same period compares to $2.27 a year ago.
The reported revenue represents a surprise of +5.25% over the Zacks Consensus Estimate of $935.05 million. With the consensus EPS estimate being $2.06, the EPS surprise was +13.59%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Charles River performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
-
Revenue- Research Models and Services: $213.07 million versus the three-analyst average estimate of $207.28 million. The reported number represents a year-over-year change of -3.6%.
-
Revenue- Discovery and Safety Assessment: $592.61 million compared to the $545.81 million average estimate based on three analysts. The reported number represents a change of -2.1% year over year.
-
Revenue- Manufacturing Solutions: $178.49 million versus the three-analyst average estimate of $182.94 million. The reported number represents a year-over-year change of -3.6%.
-
Revenue- Service: $797.92 million versus the two-analyst average estimate of $755.46 million. The reported number represents a year-over-year change of -2.3%.
-
Revenue- Product: $186.25 million compared to the $178.87 million average estimate based on two analysts. The reported number represents a change of -4.3% year over year.
-
Operating income- Research Models and Services- Non-GAAP: $57.73 million compared to the $46.59 million average estimate based on three analysts.
-
Operating income- Discovery and Safety Assessment- Non-GAAP: $141.70 million versus the three-analyst average estimate of $122.57 million.
-
Operating income- Manufacturing Solutions- Non-GAAP: $41.17 million versus the three-analyst average estimate of $48.42 million.
-
Operating income- Unallocated Corporate Overhead: -$54.27 million versus the three-analyst average estimate of -$59.34 million.
-
Operating income- Research Models and Services: $43.61 million versus the two-analyst average estimate of $27.13 million.
-
Operating income- Discovery and Safety Assessment: $93.95 million versus the two-analyst average estimate of $105.21 million.
-
Operating income- Manufacturing Solutions: -$8.62 million versus $41.50 million estimated by two analysts on average.